AOD-9604 — compound monograph
Growth-hormone C-terminal fragment analogue. Unapproved, research supply. The Institute assesses 2 outcomes for this compound and grades the strongest at very low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- AOD-9604
- Compound class
- Growth-hormone C-terminal fragment analogue
- Assessment series
- Growth-hormone axis
- Synonyms and codes
- AOD9604 · hGH fragment 176-191 (Tyr-modified) · Tyr-hGH(177-191)
- Route as evaluated
- Oral in the clinical programme; subcutaneous in research contexts
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 221231-10-3
- Molecular formula
- C78H125N23O23S2
- Average mass
- 1815.09
- Monoisotopic mass
- 1813.88
- ATC classification
- not assigned
§1.3Sequence and structural notes
A 16-residue analogue of the C-terminal region of human growth hormone, residues 177 to 191, with an additional N-terminal tyrosine. An intramolecular disulfide bridge links the two cysteine residues. The therapeutic hypothesis was that the lipolytic activity of growth hormone resides in this fragment and can be separated from its growth-promoting and diabetogenic activity.
§1.4Assessment status
The Institute assesses AOD-9604 across 2 indications and grades the strongest of them at very low certainty. Supplied as a research chemical; no marketing authorisation for the uses under which it is supplied.
Table 1. Assessed outcomes for AOD-9604, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Obesity and overweight in adults | A 12-week phase 2b trial in 300 participants did not demonstrate a statistically significant difference in body weight versus placebo at any dose | Moderate | 1 |
| Knee osteoarthritis with obesity | A small trial in knee osteoarthritis reported no significant benefit on the primary endpoint | Low | 1 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.